| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
trans-Pralsetinib (cis-Blu667) is a highly potent and selective inhibitor of rearranged during transfection (RET), with IC50 ranging from 0.3 to 0.4 nM for WT RET and four enzyme variants (V804L, V804M, M918T, CCDC6-RET), and with broad, robust and anti-tumor activity against multiple RET-driven solid tumor types.
| References |
Jason D. Brubaker, et al. Inhibitors of ret. US20170121312A1.; http://www.blueprintmedicines.com/wp-content/uploads/2017/10/BLU-667-EORTC-2017-BPM.pdf
[2]. Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.
|
|---|---|
| Additional Infomation |
Pralsetinib is a kinase inhibitor. Its mechanism of action is as a transfection rearrangement (RET) inhibitor.
See also: Pralsetinib (note moved to). |
| Molecular Formula |
C27H32FN9O2
|
|---|---|
| Molecular Weight |
533.600487709045
|
| Exact Mass |
533.266
|
| CAS # |
2097132-93-7
|
| Related CAS # |
Pralsetinib;2097132-94-8
|
| PubChem CID |
129073603
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
39
|
| Complexity |
816
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1C=NN(C=1)C1=CC=C(C=N1)[C@H](C)NC(C1(CCC(C2N=C(C=C(C)N=2)NC2C=C(C)NN=2)CC1)OC)=O
|
| InChi Key |
GBLBJPZSROAGMF-SIYOEGHHSA-N
|
| InChi Code |
InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
|
| Chemical Name |
N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
|
| Synonyms |
trans-Blu667trans-Blu 667trans-Blu-667
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~187.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.55 mg/mL (8.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8741 mL | 9.3703 mL | 18.7406 mL | |
| 5 mM | 0.3748 mL | 1.8741 mL | 3.7481 mL | |
| 10 mM | 0.1874 mL | 0.9370 mL | 1.8741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04589845
Conditions:Solid TumorsLink: https://clinicaltrials.gov/ct2/show/NCT06563999
Conditions:Lung Cancer Stage III|MutationLink: https://clinicaltrials.gov/ct2/show/NCT04302025
Conditions:Non-small Cell Lung Cancer
Title:A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:Terminated
updateDate:2026-03-05
Ctid:NCT04222972
Link: https://clinicaltrials.gov/ct2/show/NCT04222972
Conditions:RET-fusion Non Small Cell Lung Cancer|Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms by Site|Neoplasms|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Diseases|Head and Neck Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Germ Cell and Embryonal|Neoplasms, Nerve TissueLink: https://clinicaltrials.gov/ct2/show/NCT07418879
Conditions:Non-small Cell Lung Cancer|RET Fusion|PralsetinibLink: https://clinicaltrials.gov/ct2/show/NCT07010393
Conditions:Thyroid NeoplasmsLink: https://clinicaltrials.gov/ct2/show/NCT03037385
Conditions:RET-altered Non Small Cell Lung Cancer|Medullary Thyroid Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Colon Cancer|RET-altered Solid Tumors|Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Thyroid Diseases|Thyroid Neoplasm|Thyroid Cancer, Papillary|Carcinoma, Neuroendocrine|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms by Site|Neoplasms|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Neoplasms|Endocrine System Diseases|Endocrine Gland Neoplasm|Head and Neck Neoplasms|Adenocarcinoma, Papillary|Adenocarcinoma|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Neuroendocrine Tumors|Neuroectodermal Tumors|Neoplasms, Germ Cell and Embryonal|Neoplasms, Nerve Tissue|Colonic Neoplasms|Colorectal Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasm|Digestive System Disease|Gastrointestinal Disease|Colonic Diseases|Intestinal DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT05525858
Conditions:Solid Tumor|Advanced Solid Tumor|Metastatic CancerLink: https://clinicaltrials.gov/ct2/show/NCT04632992
Conditions:Advanced Unresectable or Metastatic Solid MalignancyLink: https://clinicaltrials.gov/ct2/show/NCT06482086
Conditions:Locally Advanced Thyroid Gland CarcinomaLink: https://clinicaltrials.gov/ct2/show/NCT04760288
Conditions:Medullary Thyroid CancerLink: https://clinicaltrials.gov/ct2/show/NCT04591431
Conditions:Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other CancerLink: https://clinicaltrials.gov/ct2/show/NCT04204928
Conditions:Non-Small Cell Lung Cancer|Medullary Thyroid CancerProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
